martes, 31 de enero de 2023

Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma | NEJM

Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma | NEJM

No hay comentarios:

Publicar un comentario